Animation of personal itemsAnimation of personal itemsAnimation of personal itemsAnimation of personal itemsAnimation of personal items
Animation of personal itemsAnimation of personal itemsAnimation of personal items
Animation of personal itemsAnimation of personal itemsAnimation of personal items

A mucoactive agent*
that fits into patients’ lives

Visual of BRONCHITOL Inhaler and Blister Pack

*The precise mechanism of action of BRONCHITOL in improving pulmonary
function in cystic fibrosis (CF) patients is unknown.

BRONCHITOL is not intended to be used as a rescue medication.
Inhaler and blister pack are not actual size and are for representation only.
Use an inhaled bronchodilator 5–15 minutes before taking BRONCHITOL.

BRONCHITOL® (mannitol) inhalation powder—the first and only
dry powder inhaled mucoactive agent* for patients with CF

The BRONCHITOL inhaler is:

  • Compact, handheld
  • Discreet
  • Portable

BRONCHITOL requires no:

  • Nebulization
  • Refrigeration
  • Routine cleaning or maintenance

The precise mechanism of action of BRONCHITOL in improving pulmonary function in cystic fibrosis (CF) patients is unknown.

Administered in as little as 5 minutesBRONCHITOL Inhaler and Blister Pack

BRONCHITOL
dosing and administration

BRONCHITOL is not intended to be used as a rescue medication. Inhaler and blister pack are not actual size and are for representation only. Use an inhaled bronchodilator 5–15 minutes before taking BRONCHITOL.

In clinical studies, administration time for BRONCHITOL was approximately 5 minutes. However, administration times may vary depending on
patient-specific factors.


BRONCHITOL improves FEV1

Patients taking BRONCHITOL experienced sustained improvements in FEV1 vs control over 26 weeks.1

GlassesWatchBaseball Cap

Important Safety Information

BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).

Please see Full Prescribing Information.

SneakerCar KeysMovie Tickets

Consider these potential BRONCHITOL patients

Review profiles of potential patients for whom BRONCHITOL may be appropriate.

Chiesi CareDirect® is here to help

Discover the support benefits and services available to your eligible patients.

AlmondsJournal

Important Safety
Information

BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).

BRONCHITOL can cause bronchospasm, which can be severe in susceptible patients. Because of the risk of bronchospasm, prior to prescribing BRONCHITOL, patients must pass the BRONCHITOL Tolerance Test (BTT). The BTT must be administered under the supervision of a healthcare practitioner who can treat severe bronchospasm.

Patients who pass the BRONCHITOL tolerance test (BTT) may experience bronchospasm with add-on maintenance therapy with BRONCHITOL. Patients should premedicate with an inhaled short-acting bronchodilator prior to each administration of BRONCHITOL. If bronchospasm occurs, immediately discontinue BRONCHITOL and treat bronchospasm with an inhaled short-acting bronchodilator.

Hemoptysis can occur with BRONCHITOL use. Monitor patients with history of episodes of hemoptysis. If hemoptysis occurs, discontinue use of BRONCHITOL.

Most common adverse reactions (≥3%) include cough, hemoptysis, oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, and arthralgia.

Please see Full Prescribing Information.

Indication

BRONCHITOL® (mannitol) inhalation powder is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use BRONCHITOL only in adults who have passed the BRONCHITOL Tolerance Test.

Please see Full Prescribing Information.

Reference: 1. BRONCHITOL® (mannitol) inhalation powder Prescribing Information. 2020.